




# **EXPERT PERSPECTIVES**

Join us for an exclusive broadcast

**June 14, 2023**

Please see full Prescribing Information, including Boxed Warning, inside the invitation.



## Join the conversation about once-daily AUSTEDO XR, now available

The launch of once-daily AUSTEDO XR is under way, and registration for an upcoming broadcast has begun. Led by experts in psychiatry and movement disorders, this broadcast will focus on the recently approved once-daily AUSTEDO XR. This is an excellent opportunity to stay up-to-date about a once-daily treatment option for your patients with tardive dyskinesia (TD).

Don't miss your chance to be a part of this informative and exciting event. Also available is the opportunity to join the conversation with other healthcare professionals live at one of the designated venues set up across the country. To find out more, visit the sign-up link below.

Experts will share perspectives on the impact of TD and how to manage patients with AUSTEDO XR over the long term.

There will be an opportunity to ask questions and share insights with peers.

### REGISTRATION IS NOW OPEN!

**4 broadcasts on  
Wednesday, June 14, 2023  
12:00 PM, 3:00 PM, 7:00 PM, and 9:30 PM ET**

#### INDICATIONS AND USAGE

AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

#### IMPORTANT SAFETY INFORMATION

**Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.**

**Please see additional Important Safety Information throughout and full Prescribing Information, including Boxed Warning, inside the invitation.**

### Meet Our Presenters



#### Gus Alva, MD, DFAPA

ATP Clinical Research  
Costa Mesa, California



#### Rajeev Kumar, MD, FRCPC

Medical Director  
Rocky Mountain Movement  
Disorders Center  
Englewood, Colorado

**Contraindications:** AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.

**Clinical Worsening and Adverse Events in Patients with Huntington's Disease:** AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

**QTc Prolongation:** AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

**Neuroleptic Malignant Syndrome (NMS),** a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information, including Boxed Warning, attached inside.**



**Register now to secure your spot.**

**SCAN TO REGISTER**

**[https://www.inceptionmeetings.com/  
tevanationalbroadcast](https://www.inceptionmeetings.com/tevanationalbroadcast)**

The launch of once-daily AUSTEDO XR is under way, and registration for an upcoming broadcast has begun. Led by experts in psychiatry and movement disorders, this broadcast will focus on the recently approved once-daily AUSTEDO XR. This is an excellent opportunity to stay up-to-date about a once-daily treatment option for your patients with tardive dyskinesia (TD).

Don't miss your chance to be a part of this informative and exciting event. Also available is the opportunity to join the conversation with other healthcare professionals live at one of the designated venues set up across the country. To find out more, visit the sign-up link below.

Experts will share perspectives on the impact of TD and how to manage patients with AUSTEDO XR over the long term.

There will be an opportunity to ask questions and share insights with peers.

## REGISTRATION IS NOW OPEN!

**4 broadcasts on  
 Wednesday, June 14, 2023  
 12:00 PM, 3:00 PM, 7:00 PM, and 9:30 PM ET**

### INDICATIONS AND USAGE

AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

### IMPORTANT SAFETY INFORMATION

**Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.**

**Please see additional Important Safety Information throughout and full Prescribing Information, including Boxed Warning, inside the invitation.**

### IMPORTANT SAFETY INFORMATION (continued)

**Akathisia, Agitation, and Restlessness:** AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

**Parkinsonism:** AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

**Sedation and Somnolence:** Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

**Hyperprolactinemia:** Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.

**Binding to Melanin-Containing Tissues:** Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

**Common Adverse Reactions:** The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

**Please see full Prescribing Information, including Boxed Warning, attached below.**

You may choose to have your name removed from our mailing list at any time by writing us at: Teva/Privacy Officer, 400 Interpace Parkway, Building A, Parsippany, NJ 07054

AUS-45393

**HIGHLIGHTS OF PRESCRIBING INFORMATION**  
 These highlights do not include all the information needed to use AUSTEDO XR or AUSTEDO safely and effectively. See full prescribing information for AUSTEDO XR and AUSTEDO.  
 AUSTEDO® XR (deutetrabenazine) extended-release tablets, for oral use  
 AUSTEDO® (deutetrabenazine) tablets, for oral use  
 Initial U.S. Approval: 2017

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON'S DISEASE	
See full prescribing information for complete boxed warning.	
<ul style="list-style-type: none"> <li>Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease (5.1)</li> <li>Balance risks of depression and suicidality with the clinical need for treatment of chorea when considering the use of AUSTEDO XR or AUSTEDO (5.1)</li> <li>Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior (5.1)</li> <li>Inform patients, caregivers, and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician (5.1)</li> <li>Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation (5.1)</li> <li>AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression (4, 5.1)</li> </ul>	
RECENT MAJOR CHANGES	
AUSTEDO XR (added throughout the Prescribing Information)	2/2
Dosage and Administration (2.1)	5/2
Dosage and Administration (2.1, 2.2)	2/2
INDICATIONS AND USAGE	
AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of:	
<ul style="list-style-type: none"> <li>Chorea associated with Huntington's disease (1)</li> <li>Tardive dyskinesia (1)</li> </ul>	
DOSAGE AND ADMINISTRATION	
Recommended Starting Dosage	AUSTEDO XR
	12 mg once daily (12 mg per day)
	AUSTEDO
	6 mg twice daily (12 mg per day)
<ul style="list-style-type: none"> <li>Titrate at weekly intervals by 6 mg per day based on reduction of chorea or tardive dyskinesia, tolerability, up to a maximum recommended daily dosage of 48 mg (2.1)</li> <li>Administer AUSTEDO XR with or without food in once-daily doses (2.1)</li> <li>Administer AUSTEDO with food and administer total daily dosages of 12 mg or above in two divided doses (2.1)</li> </ul>	



Teva Pharmaceuticals  
15618 W. 99th St  
Lenexa, KS 66219

---

## EXPERT PERSPECTIVES

Join us for an exclusive broadcast

**June 14, 2023**



[Name]  
[Address 1 field]  
[Address 2 field]  
[Town, State Zip]

# Layout Indicator

## AUS-45791 AUSTEDO XR National Broadcast Print Invite

Please note, this layout indicator is for illustrative purposes only and is not intended for content review.



Front Cover  
(9"W × 6"H)



Inside Half Open  
(9"W × 12"H)



Inside Full Open  
(9"W × 17.875"H)



Outside Full Open  
(9"W × 17.875"H)



Back Cover  
(9"W × 6"H)

Prescribing Information  
(folded to 5.5" × 4.25")  
spot glued on inside bottom panel